ArticleBMC health services research2025
Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases.
Ziying Zhao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.